keyword
https://read.qxmd.com/read/38604463/what-have-we-learned-on-pre-very-early-and-early-systemic-sclerosis-microcirculatory-pathophysiology-a-scoping-review
#1
REVIEW
Joana Caetano, Luís Monteiro Rodrigues, José Delgado Alves
OBJECTIVE: Microvascular dysfunction is an early event in the pathogenesis of systemic sclerosis (SSc). The objective of this scoping review is to update the current information and the level of knowledge about the mechanisms of microvascular dysfunction in pre-SSc, very early diagnosis of SSc (VEDOSS) and early SSc. METHODS: A PubMed® database search allowed us to include original data from full-length articles in English in which the main topic was microvascular dysfunction in pre-SSC, VEDOSS or early SSc...
April 9, 2024: Autoimmunity Reviews
https://read.qxmd.com/read/38603983/measurement-of-developmental-and-behavioral-concerns-in-toddlers-with-tuberous-sclerosis-complex
#2
JOURNAL ARTICLE
Nicole M McDonald, Sydney Jacobs, Carly Hyde, Connie Kasari, Shafali S Jeste
BACKGROUND: The TAND (Tuberous Sclerosis Complex [TSC]-Associated Neuropsychiatric Disorders) Checklist was developed as a clinical screener for neurodevelopmental disorders in TSC. Most studies have described patterns in older children and adults. This study sought to better understand behavioral concerns as measured by the TAND Checklist in young children with TSC. METHODS: We examined patterns of caregiver responses to the TAND Checklist in 90 toddlers with TSC (12 to 23 months n = 60; 24 to 36 months n = 30) through data collected during baseline visits across two TSC early intervention studies...
March 22, 2024: Pediatric Neurology
https://read.qxmd.com/read/38585351/low-contrast-visual-acuity-test-is-associated-with-central-inflammation-and-predicts-disability-development-in-newly-diagnosed-multiple-sclerosis-patients
#3
JOURNAL ARTICLE
Ettore Dolcetti, Fabio Buttari, Antonio Bruno, Federica Azzolini, Luana Gilio, Veronica Di Caprio, Gianluca Lauritano, Angela Borrelli, Giovanni Galifi, Roberto Furlan, Annamaria Finardi, Alessandra Musella, Livia Guadalupi, Georgia Mandolesi, Valentina Rovella, Diego Centonze, Mario Stampanoni Bassi
INTRODUCTION: The visual system is a prominent site of damage in MS since the earliest phases of the disease. Altered low-contrast visual acuity (LCVA) test has been associated with visual impairment and retinal degeneration, predicting medium- and long-term disability. However, it is unclear whether LCVA may also represent a reliable measure of neuroinflammation and a predictor of disease evolution in the very early stages of MS. METHODS: We explored in a group of 76 consecutive newly diagnosed relapsing-remitting MS (RR-MS) patients without visual impairment or altered visual evoked potentials, the association between LCVA scores at 2...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38552324/efficacy-of-methylprednisolone-in-very-early-systemic-sclerosis-results-of-the-hit-hard-and-early-randomized-controlled-trial
#4
JOURNAL ARTICLE
Brigit E Kersten, Jacqueline M J Lemmers, Amber Vanhaecke, Arthiha Velauthapillai, Wieneke M T van den Hombergh, Frank H J van den Hoogen, Cornelia H M van den Ende, Vanessa Smith, Madelon C Vonk
OBJECTIVE: We hypothesized that glucocorticoids would induce remission in very early Systemic Sclerosis patients by inhibition of inflammation driving the disease. We examined the efficacy and safety of methylprednisolone in very early Systemic Sclerosis. METHODS: In this trial adults with puffy fingers for less than three years, specific auto-antibodies and meeting the Very Early Diagnosis of Systemic Sclerosis criteria were randomly assigned (2:1) to methylprednisolone 1000 mg intravenously or placebo for 3 consecutive days 3 times with monthly intervals...
March 29, 2024: Rheumatology
https://read.qxmd.com/read/38466107/ocular-involvement-in-systemic-sclerosis-updated-review-and-new-insights-on-microvascular-impairment
#5
REVIEW
Matteo Mario Carlà, Gloria Gambini, Tomaso Caporossi, Federico Giannuzzi, Francesco Boselli, Emanuele Crincoli, Matteo Ripa, Stanislao Rizzo
Systemic sclerosis (SSc) is a chronic multisystemic disease characterized by immunological activation, diffuse vasculopathy, and generalized fibrosis exhibiting a variety of symptoms. A recognized precursor of SSc is Raynaud's phenomenon, which is part of the very early disease of systemic sclerosis (VEDOSS) in combination with nailfold videocapillaroscopy (NVC) impairment. The pathophysiology of ocular involvement, alterations in internal organs, and body integumentary system involvement in SSc patients are complicated and poorly understood, with multiple mechanisms presumptively working together...
March 11, 2024: Ocular Immunology and Inflammation
https://read.qxmd.com/read/38444472/alemtuzumab-infusion-associated-reactions-and-laboratory-changes-in-patients-with-relapsing-remitting-multiple-sclerosis-at-baseline-and-first-year-follow-up
#6
JOURNAL ARTICLE
Furkan Saridas, Filiz Mercan Saridas, Emine Rabia Koc, Omer Faruk Turan
BACKGROUND: Alemtuzumab (ATZ) is an anti-CD52 humanized monoclonal antibody indicated for treating highly active relapsing-remitting MS (RRMS). It alters the regulation of the immune system by depleting circulating lymphocytes. Changes in blood cell count, infusion-related reactions, and changes in vital parameters can be seen in the early period with ATZ. AIM: Changes in blood tests, serum tests, vital parameters, and characteristics of infusion-associated reactions (IARs) observed during the first course of ATZ treatment and thereafter were evaluated...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38366245/-systemic-sclerosis
#7
REVIEW
A-M Faber, T Krieg, N Hunzelmann
BACKGROUND: Systemic sclerosis (SSc) is a very heterogeneous, chronic, rare, but socioeconomically important disease with a severe disease course and severe impairment of the quality of life of affected patients. OBJECTIVES: Overview of the current state of research on the pathogenesis, diagnosis and therapy of SSc. METHODS: A literature search was performed. RESULTS: The pathogenesis of SSc is not fully understood...
March 2024: Dermatologie (Heidelb)
https://read.qxmd.com/read/38344341/fulminant-multiple-sclerosis-versus-autoimmune-encephalitis-a-case-report
#8
Parastesh Rezvanian, Yalda Shams, Farinaz Tabibian, Vahid Shaygannejad
KEY CLINICAL MESSAGE: This case highlights the importance of early diagnosis and treatment in prognosis of fulminant multiple sclerosis, and its similar management with autoimmune encephalitis in some clinical settings, in which these diseases are indistinguishable. This case also supports the use of rituximab in these patients with an adequate response to plasmapheresis. ABSTRACT: Early diagnosis and treatment of fulminant multiple sclerosis (MS), also known as Marburg' or malignant variant of MS (MVMS), is of great value in reducing morbidity and mortality...
February 2024: Clinical Case Reports
https://read.qxmd.com/read/38251553/the-role-of-skin-ultrasound-in-systemic-sclerosis-looking-below-the-surface-to-understand-disease-evolution
#9
REVIEW
Gemma Lepri, Michael Hughes, Yannick Allanore, Christopher P Denton, Daniel E Furst, Yukai Wang, Tânia Santiago, Ilaria Galetti, Francesco Del Galdo, Dinesh Khanna, Marco Matucci-Cerinic
Skin ultrasound has shown promising results in the evaluation of skin involvement in patients with systemic sclerosis, as substantiated by a recent systematic literature review from the World Scleroderma Foundation Skin Ultrasound Working Group. In this Viewpoint, we will discuss the role of ultrasound in evaluating skin involvement in patients with systemic sclerosis, particularly the possibility of using this technique to detect an early subclinical skin involvement from the very early phase, suggesting its possible use in both diagnosis and disease follow-up...
July 2023: Lancet Rheumatology
https://read.qxmd.com/read/38251534/beyond-very-early-systemic-sclerosis-deciphering-pre%C3%A2-scleroderma-and-its-trajectories-to-open-new-avenues-for-preventive-medicine
#10
REVIEW
Alain Lescoat, Silvia Bellando-Randone, Corrado Campochiaro, Francesco Del Galdo, Christopher P Denton, Sue Farrington, Ilaria Galetti, Dinesh Khanna, Masataka Kuwana, Marie-Elise Truchetet, Yannick Allanore, Marco Matucci-Cerinic
The identification of individuals with systemic sclerosis in an oligosymptomatic phase preceding the very early manifestations of the disease represents a challenge in the search for a new window of opportunity in systemic sclerosis. This phase could be identified in a clinical scenario as the pre-scleroderma phase, in which the disease would still be far from systemic sclerosis-related fibrotic or irreversible manifestations in skin or organs. In this Personal View, we discuss parameters and candidate definitions for a conceptual framework of pre-scleroderma, from the identification of populations at risk to autoantibodies and their potential functional activities...
November 2023: Lancet Rheumatology
https://read.qxmd.com/read/38251485/mri-digital-artery-volume-index-davix-as-a-surrogate-outcome-measure-of-digital-ulcer-disease-in-patients-with-systemic-sclerosis-a-prospective-cohort-study
#11
JOURNAL ARTICLE
Michael Hughes, Stefano Di Donato, Klodian Gjeloshi, Giuseppina Abignano, Fiammetta Danzo, Giovanni Lettieri, Enrico De Lorenzis, Dominic Bertham, Philip O'Connor, Olga Kubassova, Jamshid Dehmeshki, Francesco Del Galdo
BACKGROUND: Vascular fibrosis is a key manifestation of systemic sclerosis that leads to the narrowing of small and medium arteries, causing vascular clinical manifestations including digital ulcers and pulmonary arterial hypertension. We investigated the potential of the MRI-based Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of vascular fibrosis by using it to quantify and predict the burden of digital ulcer disease in patients with systemic sclerosis. METHODS: Two independent cohorts of patients participating in the prospective observational study STRIKE were consecutively enrolled from the Scleroderma Clinic of the Leeds Teaching Hospitals Trust, Leeds, UK...
October 2023: Lancet Rheumatology
https://read.qxmd.com/read/38166437/control-of-disease-activity-with-large-extended-interval-dosing-of-rituximab-ocrelizumab-in-highly-active-pediatric-multiple-sclerosis
#12
JOURNAL ARTICLE
Melany Venet, Anne Lepine, Adil Maarouf, Damien Biotti, Clémence Boutiere, Olivier Casez, Mikael Cohen, Pierre Durozard, Sarah Demortière, Laetitia Giorgi, Elisabeth Maillart, Guillaume Mathey, Laure Mazzola, Audrey Rico, Jean-Philippe Camdessanche, Kumaran Deiva, Jean Pelletier, Bertrand Audoin
Recent studies in adults suggested that extended-interval dosing of rituximab/ocrelizumab (RTX/OCR) larger than 12 months was safe and could improve safety. This was an observational cohort study of very active pediatric-onset multiple sclerosis (PoMS) (median (range) age, 16 (12-17) years) treated with RTX/OCR with 6 month standard-interval dosing ( n = 9) or early extended-interval dosing ( n = 12, median (range) interval 18 months (12-25)). Within a median (range) follow-up of 31 (12-63) months after RTX/OCR onset, one patient (standard-interval) experienced relapse and no patient showed disability worsening or new T2-weighted lesions...
February 2024: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/38152088/late-onset-stiff-person-syndrome-challenges-in-diagnosis-and-management
#13
JOURNAL ARTICLE
Marinos C Dalakas, Jessica Yi
BACKGROUND: Stiff person syndrome (SPS) is a rare slowly progressive autoimmune neuronal hyperexcitability disease with very-high GAD-65 antibody titers that most commonly presents above the age of 20, with muscle stiffness, painful muscle spasms, slow gait, and falls leading to disability. In other autoimmune disorders, late-onset disease has different symptom-spectrum and outcomes, but there is no information regarding late-onset SPS (LOSPS). OBJECTIVE: Highlight delayed diagnosis and poor tolerance or incomplete response to therapies of patients with LOSPS and outline how best to increase disease awareness early at onset...
2023: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38077387/a-case-report-of-anti-gad65-antibody-positive-autoimmune-encephalitis-in-children-associated-with-autoimmune-polyendocrine-syndrome-type-ii-and-literature-review
#14
REVIEW
Tamang Sapana, Wei Li, Fengyan Tian, Wenhao Yan, Binghua Dou, Shuang Hua, Zhihong Zhuo
BACKGROUND: Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme for the synthesis of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Antibodies against glutamic acid decarboxylase (GAD) are associated with various neurologic conditions described in patients, including stiff person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extra limbic encephalitis. While there are few case reports and research on anti-GAD65 antibody-associated encephalitis in adults, such cases are extremely rare in pediatric cases...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37951096/cerebrospinal-fluid-neurofilament-light-chains-predicts-early-disease-activity-in-multiple-sclerosis
#15
JOURNAL ARTICLE
Simona Toscano, Vittorio Oteri, Clara Grazia Chisari, Chiara Finocchiaro, Salvatore Lo Fermo, Paola Valentino, Antonio Bertolotto, Mario Zappia, Francesco Patti
BACKGROUND: Among biomarkers of axonal damage, neurofilament light chains (NFL) seem to play a major role, representing a promising and interesting tool in Multiple Sclerosis (MS). Our aim was to explore the predictive role of cerebrospinal fluid (CSF) NFL in patients with a recent diagnosis of MS, naïve to any MS therapy. METHODS: We retrospectively collected data of patients diagnosed with MS, referred to the Neurology Clinic of the University-Hospital G...
November 7, 2023: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/37951095/clinical-and-radiologic-differences-between-early-onset-late-onset-and-very-late-onset-adult-multiple-sclerosis
#16
JOURNAL ARTICLE
Murali Palathinkara, Abrahim N Razzak, Obada E Ababneh, Delaney Cairns, Ahmed Z Obeidat
BACKGROUND: Previous studies suggested possible differences in clinical and radiologic characteristics between early-onset multiple sclerosis (EOMS) and late-onset MS (LOMS). However, differences between LOMS and very late onset MS (VLOMS) are largely unknown. METHODS: We performed a retrospective review of medical records of patients diagnosed with MS between 8/1/2017 and 3/1/2022 at the comprehensive MS center of the Froedtert and Medical College of Wisconsin...
November 7, 2023: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/37936690/astrogliosis-in-multiple-sclerosis-and-neuro-inflammation-what-role-for-the-notch-pathway
#17
REVIEW
Pierre Mora, Candice Chapouly
Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system leading to neurodegeneration. It affects 2.3 million people worldwide, generally younger than 50. There is no known cure for the disease, and current treatment options - mainly immunotherapies to limit disease progression - are few and associated with serious side effects. In multiple sclerosis, disruption of the blood-brain barrier is an early event in the pathogenesis of lesions, predisposing to edema, excito-toxicity and inflammatory infiltration into the central nervous system...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37797392/frequency-of-diminished-ovarian-reserve-in-women-with-multiple-sclerosis-in-chile-an-exploratory-study
#18
JOURNAL ARTICLE
Carolina Pelayo, Ethel Ciampi, Bernardita Soler, Reinaldo Uribe-San-Martín, Ana Reyes, Lorena García, Adolfo Del-Canto, Leticia Gutierrez-Carquin, Antonia Barrerra-Hormazabal, Lukas Jürgensen-Heinrich, Ignacio Guzman-Cárcamo, Andrés Carvajal, Carlos Troncoso, Rodrigo Carvajal, Claudia Cárcamo
INTRODUCTION: Multiple Sclerosis (MS) is a chronic disease affecting around 2.8 million people worldwide. Two-thirds are women, and the mean age at diagnosis is about 30 years old. Social trends are moving towards older age at first pregnancy, both in women with and without MS. OBJECTIVES: To determine the frequency of diminished ovarian reserve (DOR) through anti-Mullerian Hormone (AMH) measurement in women with MS at fertile age and Healthy Females (HF) in Chile...
November 2023: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/37781240/clinical-predictors-of-neda-3-one-year-after-diagnosis-of-pediatric-multiple-sclerosis-an-exploratory-single-center-study
#19
JOURNAL ARTICLE
Filipe Palavra, Diogo Silva, Catarina Fernandes, Ricardo Faustino, Mónica Vasconcelos, Cristina Pereira, Carmen Costa, Joana Afonso Ribeiro, Joana Amaral, Conceição Robalo
INTRODUCTION: Multiple sclerosis (MS) is an inflammatory and demyelinating disorder of central nervous system that can be diagnosed in pediatric age (<18 years) in 3-5% of the cases. This early onset is associated with higher relapse rates and earlier progression to neurological disability. By using NEDA-3 (No Evidence of Disease Activity-3) criteria, we aimed to identify clinical predictors associated with absence of disease activity and control of disease progression 12 months after the diagnosis, in a cohort of pediatric-onset MS (POMS) patients regularly followed-up in our center...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/37736350/concomitant-symptomatic-cardiac-sarcoidosis-and-systemic-sclerosis-with-cardiac-involvement-a-case-report
#20
Sylvain Lemay, Carla Jeantin, Frédérique Kyomi Labelle, François Philippon, Jonathan Beaudoin, Alexandra Albert, Geneviève Dion, Mikaël Trottier, Michelle Dubois, Éric Charbonneau, Guylaine Gleeton, Charles Massé, Cédric Raymond, David H Birnie, Mario Sénéchal
Sarcoidosis and systemic sclerosis are two inflammatory multisystemic disorders of unknown etiology that may be life-threatening especially when there is cardiac involvement. Both diseases may coexist, however, there are very few case reports of patients with both cardiac sarcoidosis and systemic sclerosis in the literature. We report the case of a 72-year-old female who was initially referred for dyspnea. A chest computed tomography scan showed multiple hilar and mediastinal adenopathy with a non-specific opacity in the middle pulmonary lobe...
2023: American Journal of Cardiovascular Disease
keyword
keyword
170980
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.